Project Grant R01NS136519
- Grant Award Summary The University of Colorado received a $539,064 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 1, 2026, through June 30, 2027. This award supports fundamental research investigating the interplay between RNA binding and MECP2 (methyl-CpG-binding protein 2) genomic occupancy in neurological disease pathogenesis. The...
- Federal Grant Award Summary The National Institute of Mental Health awarded The University of Texas Southwestern Medical Center a $641,828 Project Grant effective March 5, 2026, under the Mental Health Research Grants program (CFDA 93.242) to advance understanding of Rett syndrome molecular mechanisms. The research deliverables focus on elucidating the roles of the MECP2 (Methyl-CpG-binding protein 2) protein at gene regulatory elements, specifically investigating how disruption of MECP2...
- This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $466,125.00 to New York University School of Medicine to elucidate the role of mitochondrial function in rasopathies. The research aims to analyze mitochondrial morphology and function, including enzymatic activities and oxygen consumption, in tissues from a rasopathy mouse model. It will...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $450,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Arkansas. The grant will fund research to better understand the neural mechanisms underlying healthy motor function and motor dysfunction in Rett syndrome, a neurological disorder. Specifically, the project will leverage high-dimensional geometry to investigate how...
- Grant Award Summary The University of Oklahoma Health Sciences Center received a $116,574 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 17, 2026, with completion targeted for February 28, 2029. This research initiative investigates the regulatory role of mitochondrial hydrogen peroxide (MTH2O2) in neuronal mitochondrial network...
- This $1,000,000 four-year Project Grant from the National Science Foundation's (NSF) Biological Sciences program (CFDA 47.074) will fund research at Northeastern University exploring the role of mitochondria in regulating cell fate decisions during early mammalian development. Specifically, the researchers will test the hypothesis that differential allocation of mitochondrial subtypes, which vary in biochemical properties and protein content including levels of the transcription factor TEAD4,...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $308,000 to the Regents of the University of Minnesota to investigate the impact of amyloid-beta 42 (Aβ42) on mitochondrial liquid-liquid phase separation and its effects on mitochondrial dysfunction in Alzheimer's disease. The primary goals are to: (1) Investigate the impact of Aβ42 on mitochondrial ribonucleoprotein granule dynamics in mitochondria; and (2) Use optogenetic control of Aβ42...
- This federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) to Texas A&M AgriLife Research is focused on investigating the role of the SIM2 gene in regulating mitochondrial dysfunction in Down syndrome. The $1,960,246 award, with a project period running from September 2023 to August 2026, supports three specific aims: 1) determining how SIM2 interacts with and regulates the mitochondrial respiratory complex, 2) evaluating...
- Project Grant Summary Massachusetts General Hospital's Research Management Division received a $161,880 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 1, 2026, with completion targeted for April 30, 2027. The project investigates the TWEETY homolog protein (TTYH3) and its relationship to CLN3 Batten disease, a rare lysosomal disorder...
- Federal Grant Award Summary Baylor College of Medicine received a $151,040 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective December 9, 2025, through August 31, 2028. The award funds basic neuroscience research investigating the role of hippocampal hypervascularization in Rett syndrome pathogenesis, a severe neurological disorder...
INVESTIGATING MITOCHONDRIAL DYSFUNCTION IN HUMAN ASTROCYTES WITH RTT-CAUSING MECP2 MUTATIONS - SUMMARY MUTATIONS IN THE X-LINKED GENE, METHYL-CPG BINDING PROTEIN 2 (MECP2), UNDERLIE A WIDE RANGE OF NEUROPSYCHIATRIC DISORDERS, MOST COMMONLY RETT SYNDROME (RTT), A SEVERE NEURODEVELOPMENTAL DISORDER. DESPITE NUMEROUS STUDIES, WHY THE LOSS OF MECP2 FUNCTION RESULTS IN RTT REMAINS LARGELY OBSCURE, AND IT REPRESENTS A MAJOR CHALLENGE FROM BOTH BASIC BIOLOGICAL AND THERAPEUTIC STANDPOINTS. OUR PREVIOUS STUDIES, BASED ON MOUSE MODELS, ADVANCED THE KNOWLEDGE OF THE DISEASE AND THE SPECIFIC CELL TYPES INVOLVED IN RTT NEUROPATHOLOGY. WE SHOWED THAT MUTANT GLIA, SPECIFICALLY ASTROCYTES, ARE AN INTEGRAL PART OF RTT AND THAT HEALTHY ASTROCYTES CAN RESCUE MANY ASPECTS OF THE DISEASE. HOWEVER, MOUSE MODELS DO NOT FAITHFULLY REPRESENT HUMAN RTT, WHICH IS KNOWN TO BE MORE SEVERE THAN IN MOUSE MODELS. IMPORTANTLY, HUMAN ASTROCYTES ARE SIGNIFICANTLY DIFFERENT FROM MOUSE ASTROCYTES IN THEIR STRUCTURE, GENE EXPRESSION LANDSCAPE, MITOCHONDRIAL PHYSIOLOGY, ENERGY METABOLISM, AND SUSCEPTIBILITY TO OXIDATIVE STRESS AND HYPOXIA. FOR THIS REASON, WE HAVE RECENTLY ESTABLISHED HUMAN STEM CELL-BASED MODELS FOR RTT TO INVESTIGATE THE CELLULAR AND MOLECULAR FEATURES OF HUMAN ASTROCYTES BEARING RTT-CAUSING MUTATIONS IN MECP2. OUR STUDIES REVEALED SIGNIFICANT ABERRATIONS IN MUTANT HUMAN ASTROCYTES, INCLUDING ABERRANT GENE EXPRESSION LANDSCAPE, IMPAIRED STRUCTURAL COMPLEXITY, AND IMPAIRED METABOLIC HOMEOSTASIS. IMPORTANTLY, WE SHOWED SIGNIFICANT ABERRATIONS IN MITOCHONDRIAL MORPHOLOGY AND FUNCTION IN MUTANT ASTROCYTES, SUGGESTING THAT DYSFUNCTIONAL MITOCHONDRIA LIKELY LIE AT THE HEART OF THE IMPAIRED METABOLIC HOMEOSTASIS IN MUTANT ASTROCYTES. FURTHERMORE, OUR PRELIMINARY DATA SHOW THE PRESENCE OF SENESCENCE MARKERS IN MUTANT ASTROCYTES, SUGGESTING THAT MITOCHONDRIAL DYSFUNCTION LIKELY LEADS TO CELLULAR SENESCENCE IN MUTANT ASTROCYTES. THUS, WE PROPOSE TO BUILD ON OUR RECENT FINDINGS AND IDENTIFY THE COMMON ABERRATIONS IN GENE EXPRESSION IN HUMAN ASTROCYTES BEARING DIFFERENT MECP2 MUTATIONS WITH A FOCUS ON GENES INVOLVED IN MITOCHONDRIAL FUNCTION (AIM 1), INVESTIGATE WHETHER MITOCHONDRIAL DYSFUNCTION IS A COMMON AND SPECIFIC FEATURE OF MUTANT HUMAN ASTROCYTES BEARING DIFFERENT MECP2 MUTATIONS AND WHETHER MITOCHONDRIAL DYSFUNCTION LEADS TO A SPECIFIC TYPE OF CELLULAR SENESCENCE IN ALL MUTANT ASTROCYTES (AIM 2). IMPORTANTLY, WE WILL EXAMINE WHETHER RESCUING MITOCHONDRIAL DYSFUNCTION AND/OR CELLULAR SENESCENCE COULD AMELIORATE THE STRUCTURAL AND FUNCTIONAL ABNORMALITIES WE IDENTIFIED IN MUTANT ASTROCYTES AND THEREBY THEIR ABILITY TO PROPERLY SUPPORT NEURONS (AIM 3). UNDERSTANDING THE MOLECULAR MECHANISMS THAT UNDERLIE MITOCHONDRIAL DYSFUNCTION AND ITS DOWNSTREAM EFFECTS ON MECP2 MUTANT HUMAN ASTROCYTES, AND WHETHER RESCUING MITOCHONDRIAL DYSFUNCTION AND/OR SENESCENCE COULD AMELIORATE THE STRUCTURAL AND FUNCTIONAL ABERRATIONS OF MUTANT ASTROCYTES AND CONSEQUENTLY RESTORE THEIR SUPPORT TO NEURONS, IS HIGHLY IMPORTANT FOR DEVELOPING THERAPEUTIC STRATEGIES FOR RTT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $398.8k | 4/30/26 | ||
| Not listed | $398.8k | 5/1/25 | ||
| Not listed | $398.8k | 5/3/24 | ||
| Not listed | $398.8k | 5/3/24 |